Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPd in Del(17p) Relapsed/Refractory Multiple Myeloma
NCT04124497Phase 2Active, not recruiting
- Sponsor
- Fondazione EMN Italy
- Start
- Jul 2019
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Started Jul 2019; status: active, not recruiting.
02
Drugs
daratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04124497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124497.